India was placed on a trade blacklist by the U.S. over concerns about the nation's lack of protection for pharmaceutical intellectual property. The Office of the U.S. Trade Representative released a Special 301 report objecting to aspects of the patent system of India. "The United States urges India instead to adopt policies that support both cutting-edge innovation to address important health challenges and a robust generic market," the report states.

Related Summaries